BridgeBio Pharma Profit Margin

The latest profit margin for BBIO is -102.7% as of June 2026. That compares with -329.25% in the prior-year period — up 68.8% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside BridgeBio Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, BBIO's profit margin moved from -329.25% to -102.7% — a 68.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BridgeBio Pharma's valuation or profitability profile.

Against Healthcare companies, BBIO currently prints -102.7% for profit margin, while the sector average sits near 10.58%. That is roughly 1070.7% below the sector mean. Large gaps often invite a closer look at BridgeBio Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively BridgeBio Pharma converts resources into returns. At -102.7%, BBIO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -329.25% in the prior-year period — up 68.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BBIO's profit margin (-102.7%), review year-over-year change from -329.25%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.